An Inhaled Drug Cut Lung Vessel Resistance 56 Percent More Than Placebo in a Midstage Trial

Mosliciguat cut pulmonary vascular resistance by 56.3 percent versus placebo in 135 adults with PH-ILD. Approval is still years away.

Have A Referral?